ABUS vs. AMRX, EWTX, KYMR, ARWR, JANX, NAMS, PTGX, VERA, CGON, and HRMY
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Amneal Pharmaceuticals (AMRX), Edgewise Therapeutics (EWTX), Kymera Therapeutics (KYMR), Arrowhead Pharmaceuticals (ARWR), Janux Therapeutics (JANX), NewAmsterdam Pharma (NAMS), Protagonist Therapeutics (PTGX), Vera Therapeutics (VERA), CG Oncology (CGON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.
Arbutus Biopharma vs.
Arbutus Biopharma (NASDAQ:ABUS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
Arbutus Biopharma has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Amneal Pharmaceuticals has a net margin of -6.88% compared to Arbutus Biopharma's net margin of -1,137.65%. Arbutus Biopharma's return on equity of -68.18% beat Amneal Pharmaceuticals' return on equity.
Arbutus Biopharma has higher earnings, but lower revenue than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 7 mentions for Arbutus Biopharma. Amneal Pharmaceuticals' average media sentiment score of 0.65 beat Arbutus Biopharma's score of 0.55 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.
Arbutus Biopharma received 418 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 94.12% of users gave Amneal Pharmaceuticals an outperform vote while only 71.03% of users gave Arbutus Biopharma an outperform vote.
Arbutus Biopharma presently has a consensus target price of $5.50, indicating a potential upside of 71.88%. Amneal Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 21.07%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Arbutus Biopharma is more favorable than Amneal Pharmaceuticals.
43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 4.0% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Arbutus Biopharma beats Amneal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:ABUS) was last updated on 1/18/2025 by MarketBeat.com Staff
